Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 233

1.

Obesity Trends and Body Mass Index Changes After Starting Antiretroviral Treatment: The Swiss HIV Cohort Study.

Hasse B, Iff M, Ledergerber B, Calmy A, Schmid P, Hauser C, Cavassini M, Bernasconi E, Marzolini C, Tarr PE; Swiss HIV Cohort Study, Aubert V, Barth J, Battegay M, Bernasconi E, Böni J, Bucher HC, Burton-Jeangros C, Calmy A, Cavassini M, Egger M, Elzi L, Fehr J, Fellay J, Furrer H, Fux CA, Gorgievski M, Günthard H, Haerry D, Hasse B, Hirsch HH, Hösli I, Kahlert C, Kaiser L, Keiser O, Klimkait T, Kouyos R, Kovari H, Ledergerber B, Martinetti G, Martinez de Tejada B, Metzner K, Müller N, Nadal D, Pantaleo G, Rauch A, Regenass S, Rickenbach M, Rudin C, Schöni-Affolter F, Schmid P, Schultze D, Schüpbach J, Speck R, Staehelin C, Tarr P, Telenti A, Trkola A, Vernazza P, Weber R, Yerly S.

Open Forum Infect Dis. 2014 Jul 1;1(2):ofu040. doi: 10.1093/ofid/ofu040. eCollection 2014 Sep.

2.

Decision Making in Trauma Settings: Simulation to Improve Diagnostic Skills.

Murray DJ, Freeman BD, Boulet JR, Woodhouse J, Fehr JJ, Klingensmith ME.

Simul Healthc. 2015 Feb 23. [Epub ahead of print]

PMID:
25710315
3.

Increased mortality after a first myocardial infarction in human immunodeficiency virus-infected patients; a nested cohort study.

Carballo D, Delhumeau C, Carballo S, Bähler C, Radovanovic D, Hirschel B, Clerc O, Bernasconi E, Fasel D, Schmid P, Cusini A, Fehr J, Erne P, Keller PF, Ledergerber B, Calmy A; Swiss HIV Cohort Study and AMIS registry.

AIDS Res Ther. 2015 Feb 22;12:4. doi: 10.1186/s12981-015-0045-z. eCollection 2015.

4.

[Yellow stains and what now?].

Vadasz V, Fehr J, Gerth-Kahlert C.

Ophthalmologe. 2014 Dec;111(12):1213-6. doi: 10.1007/s00347-014-3105-1. German. No abstract available.

PMID:
25475190
5.

Impact of body weight on virological and immunological responses to efavirenz-containing regimens in HIV-infected, treatment-naive adults.

Marzolini C, Sabin C, Raffi F, Siccardi M, Mussini C, Launay O, Burger D, Roca B, Fehr J, Bonora S, Mocroft A, Obel N, Dauchy FA, Zangerle R, Gogos C, Gianotti N, Ammassari A, Torti C, Ghosn J, Chêne G, Grarup J, Battegay M; Efavirenz, Obesity Project Team on behalf of Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord.

AIDS. 2015 Jan 14;29(2):193-200. doi: 10.1097/QAD.0000000000000530.

PMID:
25426810
6.

Low isoniazid and rifampicin concentrations in TB/HIV co-infected patients in Uganda.

Wiltshire CS, Lamorde M, Scherrer A, Musaazi J, Corti N, Allan B, Nakijoba R, Nalwanga D, Henning L, Von Braun A, Okware S, Castelnuovo B, Kambugu A, Fehr J.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19585. doi: 10.7448/IAS.17.4.19585. eCollection 2014.

7.

Loss to follow-up of HIV-infected women after delivery: The Swiss HIV Cohort Study and the Swiss Mother and Child HIV Cohort Study.

Aebi-Popp K, Kouyos R, Bertisch B, Staehelin C, Hoesli I, Rickenbach M, Thorne C, Grawe C, Bernasconi E, Cavassini M, de Tejada BM, Stoeckle M, Lecompte T, Rudin C, Fehr J.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19535. doi: 10.7448/IAS.17.4.19535. eCollection 2014.

8.

The PROTEA trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV-1 RNA below 50 copies/mL.

Antinori A, Arribas J, Fehr J, Girard PM, Horban A, Hill A, van Delft Y, Moecklinghoff C, Hill A.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19525. doi: 10.7448/IAS.17.4.19525. eCollection 2014.

9.

Gender inequalities in the response to combination antiretroviral therapy over time: the Swiss HIV Cohort Study.

Rosin C, Elzi L, Thurnheer C, Fehr J, Cavassini M, Calmy A, Schmid P, Bernasconi E, Battegay M.

HIV Med. 2015 May;16(5):319-25. doi: 10.1111/hiv.12203. Epub 2014 Oct 20.

PMID:
25329751
10.

"Fighting an uphill battle": experience with the HCV triple therapy: a qualitative thematic analysis.

Rasi M, Künzler-Heule P, Schmid P, Semela D, Bruggmann P, Fehr J, Saxer S, Nicca D.

BMC Infect Dis. 2014 Sep 18;14:507. doi: 10.1186/1471-2334-14-507.

11.

[Treatment of hepatitis C - an imminent revolution].

Schärer V, Bruggmann P, Müllhaupt B, Fehr J.

Praxis (Bern 1994). 2014 Sep 17;103(19):1123-31. doi: 10.1024/1661-8157/a001782. German.

PMID:
25228574
12.

[Psychosocial aspects on the treatment of HIV-infection].

Battegay M, Haerry DH, Fehr J, Staehelin C, Wandeler G, Elzi L.

Ther Umsch. 2014 Aug;71(8):509-13. doi: 10.1024/0040-5930/a000545. Review. German.

PMID:
25093317
13.

[Hepatitis B and C in HIV coinfection].

Fehr J, Schärer V, Hirzel C, Rauch A.

Ther Umsch. 2014 Aug;71(8):490-6. doi: 10.1024/0040-5930/a000542. Review. German.

PMID:
25093314
14.

Virologic and immunologic responses in treatment-naive patients to ritonavir-boosted atazanavir or efavirenz with a common backbone.

Wang Q, Young J, Bernasconi E, Vernazza P, Calmy A, Cavassini M, Furrer H, Fehr J, Bucher HC, Battegay M; Swiss HIV Cohort Study.

HIV Clin Trials. 2014 May-Jun;15(3):92-103. doi: 10.1310/hct1503-92.

PMID:
24947533
15.

Efficacy of lead-in silibinin and subsequent triple therapy in difficult-to-treat HIV/hepatitis C virus-coinfected patients.

Braun DL, Rauch A, Durisch N, Eberhard N, Anagnostopoulos A, Ledergerber B, Metzner KJ, Böni J, Weber R, Fehr J.

HIV Med. 2014 Nov;15(10):625-30. doi: 10.1111/hiv.12166. Epub 2014 Jun 4.

PMID:
24894776
16.

[Limitations of medicine:diagnosis and therapy of <<inflammatory>> back pain].

Scharer V, Hafner R, Ciurea A, Henning L, Somoskovi A, Weber R, Fehr J.

Praxis (Bern 1994). 2014 Mar 12;103(6):337-40. Review. German.

PMID:
24712089
17.

Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study.

Clotet B, Feinberg J, van Lunzen J, Khuong-Josses MA, Antinori A, Dumitru I, Pokrovskiy V, Fehr J, Ortiz R, Saag M, Harris J, Brennan C, Fujiwara T, Min S; ING114915 Study Team.

Lancet. 2014 Jun 28;383(9936):2222-31. doi: 10.1016/S0140-6736(14)60084-2. Epub 2014 Apr 1.

PMID:
24698485
18.

Infections with the tick-borne bacterium "Candidatus Neoehrlichia mikurensis" mimic noninfectious conditions in patients with B cell malignancies or autoimmune diseases.

Grankvist A, Andersson PO, Mattsson M, Sender M, Vaht K, Höper L, Sakiniene E, Trysberg E, Stenson M, Fehr J, Pekova S, Bogdan C, Bloemberg G, Wennerås C.

Clin Infect Dis. 2014 Jun;58(12):1716-22. doi: 10.1093/cid/ciu189. Epub 2014 Mar 18.

PMID:
24647019
19.

Co-trimoxazole prophylaxis is associated with reduced risk of incident tuberculosis in participants in the Swiss HIV Cohort Study.

Hasse B, Walker AS, Fehr J, Furrer H, Hoffmann M, Battegay M, Calmy A, Fellay J, Di Benedetto C, Weber R, Ledergerber B; Swiss HIV Cohort Study.

Antimicrob Agents Chemother. 2014;58(4):2363-8. doi: 10.1128/AAC.01868-13. Epub 2014 Feb 10.

20.

Reply: To PMID 23892243.

Conen A, Wang Q, Fehr J.

J Acquir Immune Defic Syndr. 2014 Apr 1;65(4):e157-8. doi: 10.1097/QAI.0000000000000088. No abstract available.

PMID:
24346643
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk